226 related articles for article (PubMed ID: 30386798)
1. Use of Rho kinase Inhibitors in Ophthalmology: A Review of the Literature.
Moshirfar M; Parker L; Birdsong OC; Ronquillo YC; Hofstedt D; Shah TJ; Gomez AT; Hoopes PCS
Med Hypothesis Discov Innov Ophthalmol; 2018; 7(3):101-111. PubMed ID: 30386798
[TBL] [Abstract][Full Text] [Related]
2. Rho-kinase Inhibitors in Ocular Diseases: A Translational Research Journey.
Singh K; Singh A
J Curr Glaucoma Pract; 2023; 17(1):44-48. PubMed ID: 37228304
[TBL] [Abstract][Full Text] [Related]
3. ROCK inhibitors in ophthalmology: A critical review of the existing clinical evidence.
Karri R; Chong EW
Clin Exp Ophthalmol; 2023 Jul; 51(5):472-483. PubMed ID: 37037790
[TBL] [Abstract][Full Text] [Related]
4. Rho kinase inhibitors-a review on the physiology and clinical use in Ophthalmology.
Moura-Coelho N; Tavares Ferreira J; Bruxelas CP; Dutra-Medeiros M; Cunha JP; Pinto Proença R
Graefes Arch Clin Exp Ophthalmol; 2019 Jun; 257(6):1101-1117. PubMed ID: 30843105
[TBL] [Abstract][Full Text] [Related]
5. Rho kinase (ROCK) inhibitors in the management of corneal endothelial disease.
Syed ZA; Rapuano CJ
Curr Opin Ophthalmol; 2021 May; 32(3):268-274. PubMed ID: 33606407
[TBL] [Abstract][Full Text] [Related]
6. The Role of Rho Kinase Inhibitors in Corneal Endothelial Dysfunction.
Okumura N; Kinoshita S; Koizumi N
Curr Pharm Des; 2017; 23(4):660-666. PubMed ID: 27917718
[TBL] [Abstract][Full Text] [Related]
7. Investigational Rho Kinase Inhibitors for the Treatment of Glaucoma.
Al-Humimat G; Marashdeh I; Daradkeh D; Kooner K
J Exp Pharmacol; 2021; 13():197-212. PubMed ID: 33664600
[TBL] [Abstract][Full Text] [Related]
8. Rho-kinase (ROCK) Inhibitors - A Neuroprotective Therapeutic Paradigm with a Focus on Ocular Utility.
Abbhi V; Piplani P
Curr Med Chem; 2020; 27(14):2222-2256. PubMed ID: 30378487
[TBL] [Abstract][Full Text] [Related]
9. ROCK Inhibitors in Corneal Diseases and Glaucoma-A Comprehensive Review of These Emerging Drugs.
Pagano L; Lee JW; Posarelli M; Giannaccare G; Kaye S; Borgia A
J Clin Med; 2023 Oct; 12(21):. PubMed ID: 37959203
[TBL] [Abstract][Full Text] [Related]
10. Rho-kinase inhibitors in the management of glaucoma.
Berrino E; Supuran CT
Expert Opin Ther Pat; 2019 Oct; 29(10):817-827. PubMed ID: 31573364
[No Abstract] [Full Text] [Related]
11. An update on ripasudil for the treatment of glaucoma and ocular hypertension.
Testa V; Ferro Desideri L; Della Giustina P; Traverso CE; Iester M
Drugs Today (Barc); 2020 Sep; 56(9):599-608. PubMed ID: 33025953
[TBL] [Abstract][Full Text] [Related]
12. Rho kinase inhibitors for treatment of glaucoma.
Mandell KJ; Kudelka MR; Wirostko B
Expert Rev Ophthalmol; 2011; 6(6):611-622. PubMed ID: 30613208
[TBL] [Abstract][Full Text] [Related]
13. Rho-associated kinase inhibitors: a novel glaucoma therapy.
Inoue T; Tanihara H
Prog Retin Eye Res; 2013 Nov; 37():1-12. PubMed ID: 23770081
[TBL] [Abstract][Full Text] [Related]
14. Rho kinase inhibition by fasudil ameliorates diabetes-induced microvascular damage.
Arita R; Hata Y; Nakao S; Kita T; Miura M; Kawahara S; Zandi S; Almulki L; Tayyari F; Shimokawa H; Hafezi-Moghadam A; Ishibashi T
Diabetes; 2009 Jan; 58(1):215-26. PubMed ID: 18840783
[TBL] [Abstract][Full Text] [Related]
15. Impact of the clinical use of ROCK inhibitor on the pathogenesis and treatment of glaucoma.
Honjo M; Tanihara H
Jpn J Ophthalmol; 2018 Mar; 62(2):109-126. PubMed ID: 29445943
[TBL] [Abstract][Full Text] [Related]
16. Role of the Rho GTPase/Rho kinase signaling pathway in pathogenesis and treatment of glaucoma: Bench to bedside research.
Rao PV; Pattabiraman PP; Kopczynski C
Exp Eye Res; 2017 May; 158():23-32. PubMed ID: 27593914
[TBL] [Abstract][Full Text] [Related]
17. AMA0076, a novel, locally acting Rho kinase inhibitor, potently lowers intraocular pressure in New Zealand white rabbits with minimal hyperemia.
Van de Velde S; Van Bergen T; Sijnave D; Hollanders K; Castermans K; Defert O; Leysen D; Vandewalle E; Moons L; Stalmans I
Invest Ophthalmol Vis Sci; 2014 Feb; 55(2):1006-16. PubMed ID: 24474276
[TBL] [Abstract][Full Text] [Related]
18. Rho/Rho-associated kinase pathway in glaucoma (Review).
Wang J; Liu X; Zhong Y
Int J Oncol; 2013 Nov; 43(5):1357-67. PubMed ID: 24042317
[TBL] [Abstract][Full Text] [Related]
19. New therapeutic modality for corneal endothelial disease using Rho-associated kinase inhibitor eye drops.
Koizumi N; Okumura N; Ueno M; Kinoshita S
Cornea; 2014 Nov; 33 Suppl 11():S25-31. PubMed ID: 25289721
[TBL] [Abstract][Full Text] [Related]
20. A Highly Selective Rho-Kinase Inhibitor (ITRI-E-212) Potentially Treats Glaucoma Upon Topical Administration With Low Incidence of Ocular Hyperemia.
Hsu CR; Chen YH; Liu CP; Chen CH; Huang KK; Huang JW; Lin MN; Lin CL; Chen WR; Hsu YL; Lee TC; Chou SH; Tu CM; Hwang CS; Huang YC; Lu DW
Invest Ophthalmol Vis Sci; 2019 Feb; 60(2):624-633. PubMed ID: 30735565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
